Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Punicalin is a natural ellagitannin found in pomegranate (*Punica granatum*) and is a structural derivative of punicalagin, specifically lacking the hexahydroxy-diphenic acid (HHDP) moiety. It functions as a selective inhibitor of **Protein Disulfide Isomerase Family A Member 3 (PDIA3)**, also known as ERp57, which is a chaperone protein primarily located in the endoplasmic reticulum involved in protein folding and disulfide bond formation. Research indicates that punicalin exhibits higher selectivity for PDIA3 over PDIA1 compared to punicalagin. By binding to PDIA3, punicalin induces thermal destabilization of the protein, leading to the formation and accumulation of intracellular protein aggregates. This mechanism makes it a compound of interest for the treatment of pathologies where PDIA3 is overexpressed or implicated, such as glioblastoma, inflammatory conditions, and neurodegenerative diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on punicalin.